Patients and health professionals are encouraged to periodically check this “What’s New” section of the Formulary website for information and updates as they become available.

PROVINCIAL MID-YEAR FINANCIAL UPDATE - DECEMBER 5, 2016: CHANGE TO THE MAC POLICY

The November 22, 2016 provincial mid-year financial update announced future changes to drug coverage:
http://www.saskatchewan.ca/government/news-and-media/2016/november/22/mid-year-report

Effective January 1, 2017, two intranasal corticosteroids (INCS) products will no longer be covered:
  • Fluticasone 50ug/dose nasal spray (Flonase® and generics); and
  • Triamcinolone 55ug/dose nasal spray (Nasacort® and generics).
  • Over-the-counter versions of these medications are now available for purchase without a prescription.
Effective January 16, 2017, the Drug Plan will also:
  • Change the Maximum Allowable Cost (MAC) price threshold for proton pump inhibitors (PPIs); and
  • Apply the Maximum Allowable Cost policy to intranasal corticosteroids.
DRUG
CATEGORY
MAXIMUM ALLOWABLE
COST (MAC) PRICE
THRESHOLD
DRUGS WITHIN MAXIMUM
ALLOWABLE COST (MAC) PRICE
THRESHOLD
DRUGS NOT WITHIN MAXIMUM
ALLOWABLE COST (MAC) PRICE
THRESHOLD
Proton Pump
Inhibitors
$0.20 per tablet Generic versions of:
  • pantoprazole magnesium ( Tecta®)
  • generic versions of rabeprazole ( Pariet®*
Brand and generic versions of:
  • esomeprazole ( Nexium®)
  • lansoprazole ( Prevacid®**
  • omeprazole ( Losec®**
  • pantoprazole sodium ( Pantoloc®)
Intranasal
Corticosteroids
$16.04 per unit Generic versions of:
  • beclomethasone
  • budesonide (64 mcg strength only)
  • mometasone ( Nasonex®)
Brand and generic versions of:
  • budesonide (generic and Rhinocort Turbuhaler®, 100mcg strength only)
  • ciclesonide ( Omnaris®)
  • flunisolide (generic) and generics

*      rabeprazole 20mg claims will fully adjudicate at its list price
**    omeprazole 10mg and lansoprazole (Prevacid FasTabs®) are exempt.

More information for patients:
More information for Health Professionals:

A comprehensive critical appraisal of the current clinical evidence for PPIs was completed by the Canadian Agency for Drugs and Technologies in Health (CADTH). CADTH’s work indicated all PPIs are therapeutically similar and equally effective in the majority of patients (https://www.cadth.ca/proton-pump-inhibitor-therapy).

PPIs are one of the drug classes that has been identified by Choosing Wisely Canada for deprescribing. As well, Saskatchewan’s RxFiles program recently focused on PPI deprescribing in its visits to physicians in the province. The following links provide more information on these initiatives:

WHOLESALE MARK-UP
Effective April 1, 2011, Saskatchewan no longer publishes prices that contain wholesale mark-up. Prices in the website and future formulary books will now be the price as confirmed by the manufacturer, exclusive of mark-ups.

Wholesale mark-up is allowed on specific products. As of August 1, 2014, the following mark-ups are in effect:
  • Insulins - 5%
  • Standing Offer Contract (SOC) products - 6%
  • Generic drugs - 6.5% (Effective August 1, 2014)
  • Most other drugs - 8.5%
The wholesale mark-up is capped at $50 per package size.


BLOOD GLUCOSE TEST STRIPS - APPROVED QUANTITIES
As of October 15, 2015 the number of blood glucose test strips (BGTS) covered* by the Saskatchewan Drug Plan will be based on the type of diabetes treatment a patient receives.
More information for patients about this change: More information for healthcare professionals about this change:
Information about self-monitoring of blood glucose (SMBG) and management of diabetes is available on the Canadian Diabetes Association website: The Canadian Agency for Drugs and Technologies in Health also has a number of SMBG resources for health care professionals and patients:

*Coverage is subject to usual deductibles and co-payment. Requests for strips in excess of these approved quantities will be considered based on medical criteria, on a case-by-case basis.


Some of these links may be to files that are in PDF (Portable Document Format).
You may require Adobe Reader to view these files. Click on the icon below to obtain a free copy of this reader:

get adobe reader

If you have any questions, please call our consumer line at (306) 787-3317 (local) or 1-800-667-7581 (toll-free).